The prevalence of CA I and II autoantibodies in patients with AML in this study was 76.6% and 23.3%, respectively. The presence of autoantibodies against CA I and II has been observed in many pathological conditions, such as metabolic syndrome, recurrent pregnancy loss, acute anterior uveitis, gastric cancer, Graves’ disease, preeclampsia, and rheumatoid arthritis. Here, CA1 is linked to Graves disease.